These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15075139)

  • 1. Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia.
    Wheatley K; Gray R
    Int J Epidemiol; 2004 Feb; 33(1):15-7. PubMed ID: 15075139
    [No Abstract]   [Full Text] [Related]  

  • 2. Heterogeneous loss of the Y chromosome in leukocyte lineages of donor origin after stem cell transplantation.
    Buño I; Kwon M; Balsalobre P; Serrano D; Carrión R; Gómez-Pineda A; Díez-Martín JL
    Bone Marrow Transplant; 2006 Sep; 38(6):463-5. PubMed ID: 16892070
    [No Abstract]   [Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia.
    de Labarthe A; Pautas C; Thomas X; de Botton S; Bordessoule D; Tilly H; de Revel T; Bastard C; Preudhomme C; Michallet M; Fenaux P; Bastie JN; Socié G; Cordonnier C; Dombret H;
    Bone Marrow Transplant; 2005 Apr; 35(8):767-73. PubMed ID: 15735660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of donor cell derived acute myeloid leukemia after stem cell transplantation for chronic myeloid leukemia.
    Pieroni F; Oliveira FM; Panepucci RA; Voltarelli JC; Simões BP; Falcão RP
    Bone Marrow Transplant; 2006 Apr; 37(8):801-2. PubMed ID: 16501585
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe vulgaris psoriatic patients with acute myelogenous leukaemia and resolution after allogeneic bone marrow transplantation/peripheral blood stem cell transplantation.
    He YL; Lu XJ; Qiu JY; Zhu TJ
    Chin Med J (Engl); 2005 May; 118(10):861-5. PubMed ID: 15989770
    [No Abstract]   [Full Text] [Related]  

  • 6. Graft-versus-disease effect following allogeneic transplantation for acute leukaemia.
    Rowe JM
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):485-502. PubMed ID: 18790451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation?
    Willemze R; Labar B
    Semin Hematol; 2007 Oct; 44(4):267-73. PubMed ID: 17961726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetically normal acute myeloid leukemia.
    Narimatsu H
    N Engl J Med; 2008 Aug; 359(6):652; author reply 652-3. PubMed ID: 18697248
    [No Abstract]   [Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach.
    Lodewyck T; Cornelissen JJ
    Blood Rev; 2008 Nov; 22(6):293-302. PubMed ID: 18455284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation for patients with acute myeloid leukaemia developing from severe congenital neutropenia.
    Ebihara Y; Ishikawa K; Mochizuki S; Tanaka R; Manabe A; Iseki T; Maekawa T; Tsuji K
    Br J Haematol; 2014 Feb; 164(3):459-61. PubMed ID: 24422727
    [No Abstract]   [Full Text] [Related]  

  • 12. Angiomatous nodules acquired after allogeneic stem cell transplantation.
    Braun-Falco M; Menzel H
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):123-4. PubMed ID: 18181994
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children.
    Executive Committee, American Society for Blood and Marrow Transplantation
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):500-1. PubMed ID: 17382259
    [No Abstract]   [Full Text] [Related]  

  • 14. Donor availability and clinical trials for allogeneic stem cell transplantation.
    Büchner T
    JAMA; 2009 Oct; 302(15):1647; author reply 1647-8. PubMed ID: 19843898
    [No Abstract]   [Full Text] [Related]  

  • 15. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia.
    Cordonnier C; Maury S; Esperou H; Pautas C; Beaune J; Rodet M; Lagrange JL; Rouard H; Beaumont JL; Bassompierre F; Glückman E; Kuentz M; Durand-Zaleski I
    Bone Marrow Transplant; 2005 Oct; 36(7):649-54. PubMed ID: 16044135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maximum supportive care, standard conditioning and allogeneic stem cell transplantation for elderly patients with acute myelogenous leukemia.
    Petersen FB; Ford CD
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S7-9. PubMed ID: 19561415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel RUNX1 mutation in a kindred with familial platelet disorder with propensity to acute myeloid leukaemia: male predominance of affected individuals.
    Langabeer SE; Owen CJ; McCarron SL; Fitzgibbon J; Smith OP; O'Marcaigh A; Browne P
    Eur J Haematol; 2010 Dec; 85(6):552-3. PubMed ID: 20722699
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
    Blaise DP; Michel Boiron J; Faucher C; Mohty M; Bay JO; Bardoux VJ; Perreau V; Coso D; Pigneux A; Vey N
    Cancer; 2005 Nov; 104(9):1931-8. PubMed ID: 16178004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
    Craddock CF
    Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
    Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H
    Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.